211 related articles for article (PubMed ID: 24083125)
1. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival.
Van Gompel JJ; Giannini C; Olsen KD; Moore E; Piccirilli M; Foote RL; Buckner JC; Link MJ
J Neurol Surg B Skull Base; 2012 Oct; 73(5):331-6. PubMed ID: 24083125
[TBL] [Abstract][Full Text] [Related]
2. [New system combining Hyams grading system and modified Kadish stage to evaluate the progress of esthesioneuroblastoma].
Lai YY; Lin TJ; Jiang LJ; Deng J; Zuo KJ; Zhang Y; Shi JB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 33(7):599-602. PubMed ID: 31327194
[No Abstract] [Full Text] [Related]
3. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes.
Bell D; Saade R; Roberts D; Ow TJ; Kupferman M; DeMonte F; Hanna EY
Head Neck Pathol; 2015 Mar; 9(1):51-9. PubMed ID: 24806334
[TBL] [Abstract][Full Text] [Related]
4. Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.
Vuong HG; Ngo TNM; Dunn IF
J Neurooncol; 2021 May; 153(1):15-22. PubMed ID: 33770323
[TBL] [Abstract][Full Text] [Related]
5. Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis.
Miyamoto RC; Gleich LL; Biddinger PW; Gluckman JL
Laryngoscope; 2000 Aug; 110(8):1262-5. PubMed ID: 10942123
[TBL] [Abstract][Full Text] [Related]
6. Long-term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients.
McMillan RA; Van Gompel JJ; Link MJ; Moore EJ; Price DL; Stokken JK; Van Abel KM; O'Byrne J; Giannini C; Chintakuntlawar A; Pinheiro Neto CD; Peris Celda M; Foote R; Choby G
Int Forum Allergy Rhinol; 2022 Dec; 12(12):1457-1467. PubMed ID: 35385606
[TBL] [Abstract][Full Text] [Related]
7. [Primary experience and discussion on the treatment of esthesioneuroblastoma].
Jiang LJ; Lin TJ; Huang ZQ; Zuo KJ; Zhang Y; Shi JB; Lai YY
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Jul; 56(7):719-723. PubMed ID: 34344098
[No Abstract] [Full Text] [Related]
8. Microvessel density and Ki-67 labeling index in esthesioneuroblastoma: is there a prognostic role?
Singh L; Ranjan R; Madan R; Arava SK; Deepak RK; Singh MK
Ann Diagn Pathol; 2015 Dec; 19(6):391-6. PubMed ID: 26343569
[TBL] [Abstract][Full Text] [Related]
9. Regional Recurrences and Hyams Grade in Esthesioneuroblastoma.
Ziai H; Yu E; Weinreb I; Perez-Ordonez B; Yao CMKL; Xu W; Yang D; Witterick IJ; Monteiro E; Gilbert RW; Irish JC; Gullane PJ; Goldstein DP; Ringash J; Bayley A; de Almeida JR
J Neurol Surg B Skull Base; 2021 Dec; 82(6):608-614. PubMed ID: 34745827
[No Abstract] [Full Text] [Related]
10. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome.
Malouf GG; Casiraghi O; Deutsch E; Guigay J; Temam S; Bourhis J
Eur J Cancer; 2013 Apr; 49(6):1324-34. PubMed ID: 23312882
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Profiling and Staging in Esthesioneuroblastoma: A Single-Center Cohort Study and Systematic Review.
Henson JC; Cutler CC; Cole KL; Lucke-Wold B; Khan M; Alt JA; Karsy M
World Neurosurg; 2023 Feb; 170():e652-e665. PubMed ID: 36435382
[TBL] [Abstract][Full Text] [Related]
12. [A retrospective study about 11 cases of Esthesioneuroblastomas treated in Hospital Santa Creu i Sant Pau between 2000 and 2008 and literature review].
Muñoz F; Tresserras P; Montserrat JR; Sancho FJ; Bartumeus F
Neurocirugia (Astur); 2011 Oct; 22(5):401-17; discussion 417-8. PubMed ID: 22031159
[TBL] [Abstract][Full Text] [Related]
13. Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.
Sharma S; Sharma MC; Johnson MH; Lou M; Thakar A; Sarkar C
Pathol Oncol Res; 2007; 13(2):123-9. PubMed ID: 17607373
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
McElroy EA; Buckner JC; Lewis JE
Neurosurgery; 1998 May; 42(5):1023-7; discussion 1027-8. PubMed ID: 9588546
[TBL] [Abstract][Full Text] [Related]
15. Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis.
Goshtasbi K; Abiri A; Abouzari M; Sahyouni R; Wang BY; Tajudeen BA; Hsu FPK; Cadena G; Kuan EC
Int Forum Allergy Rhinol; 2019 Sep; 9(9):1054-1062. PubMed ID: 31251848
[TBL] [Abstract][Full Text] [Related]
16. A Review on Esthesioneuroblastoma.
Rao KR; Upadhya IB
Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):1584-1590. PubMed ID: 36452592
[No Abstract] [Full Text] [Related]
17. Recurrent Esthesioneuroblastoma: Long-Term Outcomes of Salvage Therapy.
Ni G; Pinheiro-Neto CD; Iyoha E; Van Gompel JJ; Link MJ; Peris-Celda M; Moore EJ; Stokken JK; Gamez M; Choby G
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900297
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgical salvage treatment for locally recurrent esthesioneuroblastoma.
Van Gompel JJ; Carlson ML; Pollock BE; Moore EJ; Foote RL; Link MJ
Neurosurgery; 2013 Mar; 72(3):332-9; discussion 339-40. PubMed ID: 23208068
[TBL] [Abstract][Full Text] [Related]
19. Management of Esthesioneuroblastoma: A Retrospective Study of 6 Cases and Literature Review.
Alami Z; Farhane FZ; Bouziane A; Mhirech S; Amrani Joutei S; Hassani W; Bouhafa T
Case Rep Oncol; 2022; 15(1):176-186. PubMed ID: 35431860
[TBL] [Abstract][Full Text] [Related]
20. Olfactory Neuroblastomas: What Actually Happens in the Long-Term?
Mantsopoulos K; Koch M; Iro H; Constantinidis J
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
